8-KMaterial AgreementsExhibits & Filings

BIOGEN INC. 8-K Report, Material Agreement (Sep 15, 2005)

Filed September 15, 2005For Securities:BIIB

Summary

Biogen Inc. (BIIB) filed an 8-K on September 15, 2005, to report the entry into a material definitive agreement concerning equity compensation. The Compensation Committee approved the grant of approximately 1.17 million performance-based restricted stock units (RSUs) to nearly 200 employees at the director level and above, under the company's 2005 Omnibus Equity Plan. These RSUs are designed to incentivize key personnel and align their interests with the company's performance. Importantly, the vesting of these units is contingent upon the achievement of specific performance objectives over the next 12-18 months, in addition to continued employment. Notably, the CEO and Executive Chairman were not granted these specific performance-based RSUs, while other executive officers received grants ranging from 25,000 to 50,000 units.

Key Highlights

  • 1Biogen granted approximately 1.17 million performance-based restricted stock units (RSUs) on September 12, 2005.
  • 2The RSUs were awarded to approximately 200 employees at the director level and above.
  • 3The grants are part of the company's 2005 Omnibus Equity Plan.
  • 4Vesting of these RSUs is performance-based, tied to company objectives over 12-18 months and continued employment.
  • 5Key executive officers received grants, with specific amounts detailed for several individuals.
  • 6The CEO, James C. Mullen, and Executive Chairman, William H. Rastetter, were excluded from these particular RSU grants.

Frequently Asked Questions

The primary purpose of these grants is to incentivize and retain key employees at the director level and above, by aligning their compensation with the company's future performance and continued service.

The vesting is performance-based. It depends on Biogen achieving certain approved performance objectives within the next 12 to 18 months, and the employee maintaining their employment with the company throughout that period.

The filing does not explicitly state the reason for the exclusion of the CEO and Executive Chairman from these specific performance-based RSU grants. It's possible they have other compensation arrangements or their incentives are structured differently.

The filing reports the number of units (approximately 1.17 million) but does not disclose the grant date fair value or potential future value, which would depend on the stock price and achievement of performance targets.